ASCO Abstract Preview: ImClone, Genentech

---

Medarex MEDX:

Abstract No. 9010: Safety and efficacy of ipilimumab with or without prophylactic budesonide in treatment-naive and previously treated patients with advanced melanoma.

Abstract No. 3018: Long-term survival of patients with advanced melanoma who received ipilimumab administered at 10 mg/kg every three weeks for four doses (induction dosing).

Abstract No. 9025: Dose effect of ipilimumab in patients with advanced melanoma: Results from a phase II, randomized, dose-ranging study.

---

Medivation MDVN:

Abstract No. 5006: Phase I/II study of MDV3100 in patients with progressive castration-resistant prostate cancer.

---

Onyx Pharmaceuticals ONXX:

Abstract No. 4509: Randomized phase III trial of sorafenib vs. placebo in Asian patients with advanced hepatocellular carcinoma.

Abstract No. 6527: Economic evaluation of sorafenib vs. best supportive care in hepatocellular carcinoma.

OSI Pharmaceuticals OSIP:

Abstract No. 4507: A randomized, double-blind, placebo controlled, multicenter phase III trial to evaluate the efficacy and safety of adding bevacizumab to erlotinib and gemcitabine in patients with metastatic pancreatic cancer. (Note: This study previously announced failed.)

---

PDL BioPharma PDLI and Biogen Idec BIIB:

Abstract No. 9051: A multicenter phase II study of volociximab in patients with relapsed metastatic melanoma.

---

Pfizer PFE:

Abstract No. 4521: Sunitinib monotherapy in patients with advanced hepatocellular carcinoma; insights from a multidisciplinary phase II study.

Abstract No. 8015: High activity of the anti-IGF-IR antibody CP-751,871 in combination with paclitaxel and carboplatin in squamous NSCLC.

Abstract No. 9006: Axitinib (AG-013736) in patients with metastatic melanoma: A phase II study.